The surge in demand for GLP-1 drugs like Ozempic has driven interest in psyllium husk, though experts question whether it can truly replicate prescription weight-loss results.

GLP-1 drugs are being hailed as a potential 'game-changer' for America's obesity crisis, but their widespread impact is hindered by two significant inequalities. These disparities limit access and effectiveness for many who could benefit.

Large food companies are grappling with a significant challenge as GLP-1 drugs threaten billions in sales, prompting them to explore new strategies to appeal to consumers with reduced appetites.

An Illinois man, Rodney Greer, has been accused by prosecutors of impersonating doctors to secure unauthorized prescriptions for GLP-1 drugs like Ozempic and then selling them to customers.

AstraZeneca states that the market for GLP-1 drugs extends beyond just weight loss, indicating potential for these medications in treating other conditions.

GLP-1 medications like Ozempic and Wegovy are being studied for their potential beyond weight loss, specifically their ability to reduce cravings for alcohol and other addictive substances by affecting a specific brain region.

AstraZeneca's Chief Financial Officer provides insights on the company's strategy regarding GLP-1 drugs, artificial intelligence, and other key business areas.

The increasing use of GLP-1 drugs is reportedly influencing consumer behavior, leading to a resurgence in in-store clothes shopping among users.

Eli Lilly has committed $2.8 billion to a new venture, signaling a strategic move to expand its portfolio beyond its highly successful GLP-1 drugs.

Rapidly popular GLP-1 drugs, used for weight loss and diabetes, are now being associated with hair loss, according to a new study. Experts are explaining the potential reasons behind this side effect.

A new Greek study suggests that GLP-1 drugs, primarily known for treating obesity and type 2 diabetes, may also be effective in combating alcohol and other addictions. This opens a new field of potential applications for these medications.

The widespread use of GLP-1 drugs like Ozempic is causing disruptions in the wedding dress industry, as bridal designers adapt to accommodate rapid weight loss among customers.

A BMJ study suggests that weight loss drugs offer limited heart health benefits in their first year of use, prompting experts to caution that it is too soon for a final verdict. The research also decodes the strengths and weaknesses of 19 GLP-1 drugs regarding weight loss, muscle mass, and heart risk.

A new Medicare pilot program offering GLP-1 drugs for $50 to some adults aged 65 and above has raised concerns about potential drug shortages.

CVS has converted its 9,000 pharmacies into a delivery system for GLP-1 drugs, leading a top Wall Street analyst to recommend buying the company's stock.

An article provides insights into what beneficiaries can expect regarding Medicare coverage for GLP-1 medications, often used for conditions like diabetes and weight management.

GLP-1 drugs like Ozempic, while effective for weight loss, are increasingly linked to relationship changes and divorces, as patients' new habits and confidence affect their partnerships.

Research and experts are addressing the reported mood changes experienced by some individuals taking GLP-1 medications, with some feeling calmer and others describing a 'grey cloud' effect.

ResMed's stock has been downgraded by Morgan Stanley, citing concerns over Philips' re-entry into the market and potential headwinds from GLP-1 drugs.

An article explores the potential side effects associated with discontinuing and then resuming GLP-1 medications, which are commonly used for diabetes and weight management.

The article highlights three key areas where GLP-1 drugs, used for weight loss and diabetes management, are expected to see significant improvements in the near future.

Serena Williams' recent return to tennis, marked by a doubles win, has prompted a discussion about the potential use of GLP-1 medications for performance enhancement in sports.

TD Cowen has significantly increased its sales forecast for GLP-1 drugs, now projecting them to reach $150 billion. This revised outlook underscores the growing market potential and demand for this class of pharmaceuticals.

Samsung smartwatches are reportedly being developed to help monitor and track muscle loss, a potential side effect associated with GLP-1 weight-loss medications.

BTIG initiated research coverage on a biotech company with a buy rating, suggesting its experimental hair loss treatment could be a 'GLP-1 moment' for the condition, akin to the impact of GLP-1 drugs on weight loss.

New research indicates that GLP-1 medications, commonly used for type 2 diabetes and weight loss, could be associated with a decreased risk of developing certain types of cancer.

Scientists have discovered that GLP-1 based medications, such as Ozempic, Wegovy, and Mounjaro, significantly reduce the risk of cardiovascular events like heart attacks and strokes, in addition to their known benefits for diabetes and obesity.

Embecta's CEO is focusing on GLP-1 drugs and diversification through Owen Mumford to reset the company's strategy in the U.S. market.

Scientists at the Chinese University of Hong Kong are investigating the potential of popular GLP-1 weight-loss injections to aid patients recovering from severe strokes, particularly when used in conjunction with surgical procedures to remove blood clots.

The fashion industry is reportedly returning to idealizing skinniness, influenced by GLP-1 drugs and a backlash against the body positivity movement.

OneSource Specialty Pharma is making a capacity-led investment, positioning itself to capitalize on the growing market for GLP-1 drugs.

US prescription spending is projected to potentially surpass $1 trillion, with GLP-1 drugs identified as a primary driver of this increase.

Scientists have identified a minimally invasive endoscopic procedure, described as a "metabolic reset," that may help prevent weight rebound in individuals who stop taking GLP-1 drugs. This method could offer lasting weight loss maintenance.

The increasing popularity of GLP-1 drugs is leading cannabis dispensaries to rethink their product offerings and business strategies.

Insurance coverage for popular GLP-1 obesity drugs is reportedly worsening, with many plans dropping or further restricting access to these blockbuster medications.

New evidence suggests that GLP-1 medications, while primarily known for weight loss, are providing health benefits to users even if they don't experience significant weight reduction. This indicates a broader therapeutic potential for these drugs.

Experts recommend incorporating strength training to help individuals preserve muscle mass when using GLP-1 medications for weight loss, addressing a common concern among users.

Flowers Foods (FLO) is experiencing business pressure due to the rising popularity of GLP-1 weight-loss treatments and a general softening of consumer sentiment, impacting its financial outlook.

As prescriptions for GLP-1 drugs have increased, doctors are reporting thirteen unexpected benefits beyond blood sugar control and weight management. However, despite their growing use, these medications are not without risks.

The CEO of Mars has been appointed to a board role at Novo Nordisk, a major supplier of GLP-1 drugs, signaling a significant corporate development for the pharmaceutical company.

Canadian experts are weighing in on U.S. civil cases that expose how social media addiction negatively impacts youth, with an Indian news summary also highlighting the ongoing social media addiction trials.

Doctors specializing in obesity have responded to Polish singer Dorota Rabczewska (Doda), who controversially labeled individuals using GLP-1 drugs for obesity as "lazy" and "fat," claiming they choose a shortcut.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.

Evidence is piling up that GLP-1 drugs can treat addiction. We must learn from the way that obesity has been stigmatised In the years since so-called weight-loss jabs entered widespread use, there…

LifeMD has outlined a target of achieving over $250 million in annualized revenue run rate by the fourth quarter of 2026, driven by record demand for GLP-1 drugs and expanded partnerships.

New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.

GLP-1 Drugs Tied to Fewer Addictions, Overdoses in Large Study  Bloomberg.com

Indian comedian Tanmay Bhat shared his personal experience with weight loss, revealing he lost 75 kgs without GLP-1 injections but is now experimenting with them to see their effects.

Bank of America advises investors to buy stock in a coffee and peanut butter maker, citing easing concerns about a previous acquisition and the company's strong position to navigate the impact of GLP-1 drugs.

Doctors caution that while GLP-1 drugs like Ozempic show lower cancer rates in observational data, healthy-user bias and short follow-up periods mean prevention remains unproven.

GLP-1 drugs are being hailed as a potential 'game-changer' for America's obesity crisis, but two significant inequalities are hindering their widespread impact and economic viability, according to industry experts.

Hershey is exploring ways to adapt its Halloween candy offerings to align with evolving weight-loss trends and a growing focus on health, influenced by factors like GLP-1 drugs.

The CEO of Hims has responded to a lawsuit from the FTC and anticipates that prices for GLP-1 drugs will fall to $40-$50, according to CNBC.

The CEO of Cava, a major restaurant chain, stated that GLP-1 weight-loss drugs are contributing to the emergence of a 'big kids' market, with diners increasingly opting for kids' meals.

Starbucks will cease covering GLP-1 drugs prescribed for weight loss for its benefits-eligible employees starting in October, citing rising employer healthcare costs.

Bank of America's CEO has revealed that the company spends more than $250 million annually on GLP-1 drugs for its employees. This significant expenditure highlights the growing use of these medications within corporate health benefits.

A new study indicates that GLP-1 drugs, commonly used for diabetes and weight loss, could potentially be personalized for individuals, tailoring treatments to specific patient needs.

The Guardian is seeking input from readers who have used GLP-1 drugs such as Wegovy and Mounjaro for weight loss but have not experienced the desired effects, acknowledging that these drugs are ineffective for a small percentage of users.

Australia's Therapeutic Goods Administration (TGA) has issued a warning about a 'rare but severe' eye disorder, Non-Arteritic Ischemic Optic Neuropathy (NAION), linked to GLP-1 drugs such as Ozempic, updating product information for these medications.

The potential for microdosing GLP-1 drugs for weight loss is being explored, with medical experts advising that such use should only occur under strict medical supervision.

This article discusses ways to improve metabolism and lose weight, highlighting that there are no 'magic' solutions, even with revolutionary GLP-1 drugs.

A Texas principal, Gerardo Moreno Mendez, was arrested last month and faces charges for allegedly selling GLP-1 drugs to school staff, having been hired by a second school district prior to his arrest.

Millions of Americans can now get Medicare to cover GLP-1 drugs for weight loss, a significant expansion as previously Medicare only covered these drugs for conditions like Type 2 diabetes, sleep apnea, or stroke/heart-attack risk.

Specialists warn that GLP-1 medications like Ozempic are not a 'miracle shot' for chronic obesity, requiring a comprehensive approach including healthy eating, adapted physical activity, and family doctor guidance, with a focus on maintaining muscle mass during weight loss.

Experts are explaining how GLP-1 drugs work as a component of treating chronic obesity, noting that for individuals with a BMI of 30, only a small fraction can achieve a healthy weight through diet and exercise alone.

A new study indicates that GLP-1 drugs, commonly used for weight loss, may also enhance men's fertility by improving reproductive hormones and semen parameters.

Scientists may have found a solution to the common problem of weight regain experienced by patients after discontinuing GLP-1 weight loss medications.

The Food and Drug Administration (FDA) has renewed its efforts to crack down on companies compounding GLP-1 drugs.

Reports indicate that some employers in the United States are planning to drop coverage for GLP-1 drugs by the year 2027.

New studies are exploring the potential link between Ozempic and cancer, with one study suggesting a 30% lower risk of breast cancer for GLP-1 users. Other research indicates that negative body image after weight loss can lead users to discontinue GLP-1 drugs.

Recent studies indicate that GLP-1s, commonly used for weight loss and diabetes, may both prevent cancer and slow its progression, with researchers investigating mechanisms beyond just weight loss.

Eli Lilly's management is reportedly looking to pursue additional dealmaking opportunities to further leverage the success of its GLP-1 drugs.

New research continues to explore how GLP-1 drugs, commonly used for weight loss, may impact brain function, memory, and emotion, potentially reshaping people's nervous systems. Studies now suggest these drugs could also curb addiction, cravings, anxiety, compulsive thinking, and emotional distress.

New research indicates that the reduction in obesity-related disease risk is directly tied to the amount of weight lost using GLP-1 drugs, such as Ozempic. Additionally, Lilly's Mounjaro has been found to outperform other GLP-1s for some type 2 diabetes patients.

IHE experienced a significant year, attributed to the impact of GLP-1 drugs, while IXJ is reportedly focusing on a longer-term strategic approach in the market.

GLP-1 drugs, known by names like Ozempic, Wegovy, and Mounjaro, offer benefits to the heart, kidneys, and liver, independent of weight loss. These broader effects, previously observed in animals, are now being seen in humans.

New research indicates that GLP-1 drugs, such as Ozempic and Wegovy, could potentially slow the spread of obesity-related cancers, leading to better outcomes for patients.

A new federal government pilot program is offering Medicare coverage for GLP-1 drugs specifically for weight loss, with details on cost and eligibility now available.

Users of GLP-1 weight-loss drugs are reportedly reducing their restaurant spending, leading to a noticeable impact on the restaurant industry's business performance.

Studies on GLP-1 medications, including early generations like liraglutide, have demonstrated a significant decrease in cardiovascular death, heart attack, and stroke. This finding was highlighted by a vice-president, noting that liraglutide is no longer available in Greece.

Eli Lilly's stock experienced fluctuations after the FDA released a report concerning liver failure associated with one of its GLP-1 drugs.

Articles discuss GLP-1 drugs, often touted as a "magic bullet" for weight loss, highlighting their enticing potential which now includes a new study showing they can reduce heavy drinking. Concerns over their safety still temper the widespread appeal of these medications.

Eli Lilly's stock performance is being significantly lifted by strong sales of its GLP-1 drugs, prompting analysis on whether LLY stock is a good investment.

Eli Lilly has increased its annual profit forecast, attributing the upward revision to the strong growth and demand for its GLP-1 class of drugs.

Researchers in Oklahoma have identified that the natural hormone FGF21 targets the same brain region as GLP-1 drugs and may reduce obesity by increasing metabolic rate rather than suppressing appetite.

Norwegian customs authorities reported a significant increase in the seizure of GLP-1 drugs, the active ingredient in weight loss injections, from fewer than ten in 2023 to over 6,200 last year.

GLP-1 medications like Ozempic and Mounjaro, popular for diabetes and obesity treatment, are being examined for their specific effects on the stomach and intestines.

The family behind Tapito, an iconic LA hot sauce, decided to sell their business due to a surge in demand for hot sauce and other condiments, attributed to the growing use of weight-loss drugs like GLP-1s.

New research indicates that individual genetic variations play a significant role in determining the effectiveness of GLP-1 drugs for weight loss and the likelihood of experiencing their side effects.

Equity research firm Bernstein estimates that apparel retailers could see an annual boost of up to $13 billion in spending as millions of people using GLP-1 drugs refresh their wardrobes due to weight loss.

The Indian government has issued a detailed advisory and increased regulatory surveillance on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision due to rising demand and flagged risks.

A columnist discusses her conflicted feelings as body-positivity influencers she follows begin taking GLP-1 drugs, expressing a desire for them to remain 'chubby'.

A new study indicates that the cardiovascular benefits gained from GLP-1 medications are lost more rapidly after treatment cessation than they were acquired.

Nutritionists are offering guidance on adopting 'GLP-1 friendly' diets for individuals using GLP-1 drugs for weight management, helping to decode new marketing labels from food companies targeting this demographic.

GLP-1 drugs, while offering significant therapeutic advancements, are also susceptible to misuse, raising concerns about their broader implications beyond intended medical applications.

American restaurant chains are reconsidering both menus and portion sizes after the use of so-called GLP-1 drugs, such as Ozempic, Wegovy, and Zepbound, has increased significantly.

Companies producing sauces and spices are seeing increased deal interest, as the rise of GLP-1 weight-loss drugs is reportedly leading Americans to seek out more flavorful, 'hot stuff'.

RESEARCH reveals that popular GLP-1 drugs used for weight loss can significantly increase the risk of osteoporosis and other bone diseases, as well as tendon ruptures.

A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose.

A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and that many more would like to, but cost is a barrier.

Eli Lilly's stock declined after its competitor, Novo Nordisk, announced plans to reduce the list prices for its GLP-1 class of drugs.

The initial excitement surrounding GLP-1 weight loss drugs provides insights into current market dynamics, with connections drawn to jet fuel and software sell-offs.

Researchers at UC Berkeley have identified a potential new treatment for obesity and diabetes that works by boosting internal metabolism, offering a different mechanism compared to GLP-1 drugs like Ozempic and Mounjaro.

A breast surgical oncologist outlines five daily strategies that may help reduce cancer risk and improve outcomes, including the potential role of GLP-1 drugs like Ozempic.

This article discusses five food stocks, including Smucker and Pepsi, that are recommended for purchase, detailing how they can potentially defy concerns related to GLP-1 drugs.

GLP-1 drugs are showing significant promise in treating a hormonal disorder that causes constant weight gain and forces women to shave facial hair. Patients describe the drugs as a 'godsend' for managing symptoms.

The competitive landscape between Eli Lilly and Novo Nordisk is increasingly defined by their manufacturing capabilities for GLP-1 drugs.

Pharmaceutical giants Eli Lilly and Novo Nordisk have successfully defeated an antitrust lawsuit concerning their market position in GLP-1 drugs.

In Brazilian supermarkets, GLP-1 medications like Ozempic are influencing consumer habits, leading to a reorganization of aisles where traditional items like pão de queijo are losing shelf space to healthier options like yogurt.

Canada's largest grocer, Loblaw, reported increased profits driven by sales of generic GLP-1 drugs, which are up 40% year-to-date, and a rise in bargain-hunting shoppers.

The necessity for GLP-1 drugs to remain cold is emerging as a significant growth driver for logistics giants United Parcel Service, Inc. (UPS) and FedEx Corporation (FDX). This requirement creates new opportunities in cold chain logistics.

An aesthetics company, a maker of Botox, has reported an increase in demand for treatments addressing facial volume loss, a phenomenon sometimes referred to as 'Ozempic face,' which is linked to the increased use of GLP-1 drugs.

Intuitive Surgical's stock has dropped as changes to the Affordable Care Act (ACA) and the impact of GLP-1 drugs weigh on the company's growth prospects.

A new study emphasizes the importance of monitoring frailty risks when older adults use GLP-1 drugs, suggesting potential concerns for this demographic.

An analysis explores Medicare's coverage of GLP-1 drugs and its potential implications for the future of the biotechnology sector.

The head of Biocon has issued a warning regarding GLP-1 drugs, while the CEO of Zerodha has highlighted a period of weak market demand.

With one in eight Americans now taking GLP-1 drugs, UPS is investing $48 million to enhance its cold storage capabilities. This investment aims to ensure the proper handling and delivery of these temperature-sensitive medications.

An analysis compares Eli Lilly and Viking Therapeutics, evaluating which GLP-1 stock presents a better investment opportunity.

Scott Galloway suggests that GLP-1 drugs could be a "silver bullet" for many of America's societal problems, provided obstacles are not created.

Researchers are investigating whether GLP-1 weight-loss drugs could reduce crime rates by improving impulse control and decreasing substance abuse. Initial studies on this potential link have already been conducted.

The growing popularity of GLP-1 drugs is fueling a share rally for Glanbia, a protein-powder maker.

A new study indicates that middle-aged adults using GLP-1 medications for obesity could save over $192,000 in lifetime medical costs, with even higher savings for those without college degrees.

The increasing use of GLP-1 weight-loss drugs among people in the Black diaspora is prompting discussions about how these medications might reshape perceptions of Black beauty, health, and body image.

A new generation of weight-loss therapies is under development, promising to offer improved efficacy and convenience compared to existing GLP-1 drugs like Zepbound and Wegovy.

New research and debate highlight the potential risks of rapid weight loss, particularly with GLP-1 drugs like Mounjaro, which can lead to significant muscle loss and a higher percentage of body fat, despite overall weight reduction. The article investigates the changes occurring beyond the scale.

New research continues to explore how GLP-1 drugs, commonly used for weight loss, may impact brain function, memory, and emotion, potentially reshaping people's nervous systems and influencing areas beyond metabolism.

New research indicates that GLP-1 drugs, commonly used for weight loss, could have a side effect of changing the brain and reshaping people's nervous systems.

The advent of GLP-1 drugs is influencing diet-driven shopping habits, which could have a significant impact on retailers and shopping malls. This trend arrives at a crucial time for many businesses in the retail sector.

New research indicates that GLP-1 medications are significantly reducing the demand for stomach weight-loss surgeries.

New research indicates that individuals exhibit diverse responses to GLP-1 drugs like Wegovy, with some being "super-responders" while others show no effect.

Hims & Hers is making significant investments in GLP-1 drugs, but investors are expressing a desire for the company to deliver profits in the short term.

Certain Medicare enrollees will see the cost of GLP-1 drugs reduced to $50 starting this summer. This change aims to make the medication more accessible.

New research indicates that GLP-1 receptor agonist drugs, initially used for diabetes and now popular for weight management, may also lead to a reduction in individuals' grocery spending by controlling appetite.

Eli Lilly reported a significant 56% surge in sales, primarily attributed to the booming demand for GLP-1 drugs, which overshadowed the impact of lower prices.

Articles discuss GLP-1 drugs, often touted as a "magic bullet" for weight loss, highlighting their enticing potential while also warning of their inherent dangers. The widespread appeal of these medications is tempered by concerns over their safety.

With the increasing use of GLP-1 drugs, obesity experts are now focusing on understanding 'food noise,' the internal compulsion to eat, which was previously not a primary area of study.

Biotech investor Alex Karnal has stated that GLP-1 drugs represent a 'trillion-dollar revolution' in public health, highlighting their immense potential impact on the healthcare industry.

Experts have identified five specific supplements that individuals should avoid when they are taking GLP-1 medications, such as those used for weight loss and diabetes.

New evidence suggests that GLP-1 medications provide health benefits to individuals even if they do not experience significant weight loss, expanding the understanding of their therapeutic effects.

The surging use of GLP-1 drugs is generating significant economic opportunities and creating "winners" in various industries, extending far beyond the pharmaceutical sector.

Research suggests that GLP-1 drugs such as Ozempic and Wegovy could potentially double the risk of divorce, a trend observed previously in bariatric surgery patients, according to expert warnings.

Bank of America has lowered its price target for McKesson (MCK), citing concerns over pricing pressure related to GLP-1 drugs. This adjustment reflects potential challenges for the healthcare company in the current market.

The CEO of Mars has been appointed to a board role at Novo Nordisk, a key supplier of GLP-1 drugs.

Beyond their success as weight loss medications, GLP-1 drugs are now being investigated for their potential to help mitigate the opioid crisis, which claims over 100,000 lives annually from overdoses.

Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular risk by 22%, a new study finds.

Nutrition experts are cautioning that the increasing popularity of high-protein diets, often coupled with GLP-1 drugs and low-carb eating, is causing a significant fiber deficiency among Americans.

Scientists have discovered a molecule in python blood that suppresses appetite in obese mice without the typical side effects of GLP-1 drugs, potentially paving the way for new obesity treatments.

The evidence is tantalising. But that is not the same as proof

A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.

In recent years, a class of drugs primarily used for diabetes, now famous GLP-1 drugs due to their effectiveness against obesity, have been found to...

Increasingly popular GLP-1 drugs used to treat diabetes and obesity show promise in fighting multiple substance use disorders

A preliminary study suggests that GLP-1 drugs, typically used for diabetes and weight loss, could significantly reduce the need for migraine medication in individuals suffering from chronic migraines.

GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their experiences with the medicines.

The manufacturing process for GLP-1 medications, a class of drugs used for weight loss and diabetes, is being scrutinized for its significant environmental impact.